Navigation Links
NORTHWEST BIO Announces Positive Third Quarter Progress
Date:10/6/2011

160;The NORTHWEST BIO trial is a double-blind randomized controlled trial, with a "treated" group and a "control" group, as is required for late stage clinical trials.  However, unlike other current immune therapy trials for cancer, the NORTHWEST BIO trial has been carefully designed so that it provides an opportunity for all patients in the "control group" to "cross over" and receive the DCVax® immune therapy after a certain point is passed.  As a result, the NORTHWEST BIO trial design will not only provide randomized, placebo-controlled data,  it will also allow all patients in the trial to ultimately receive the DCVax® treatment -- including the patients who are assigned to the "control group."  Physicians and patients are expressing strong interest and support for this trial design.

As part of NORTHWEST BIO's program to increase the visibility of its progress, it also announced today that it has entered into an agreement to have company information made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have corporate information disseminated to users of Standard & Poor's Market Scope Advisor, used by more than 100,000 investment advisors.  The first step under this program is a basic listing of NORTHWEST BIO in the Daily News section of Standard Corporation Records, a recognized manual for secondary trading in up to 38 states under their Blue Sky Laws, thereby qualifying NWBO for trading in those states.

Standard and Poor's also makes available a weekly updated Stock Report on Company initiatives and strategy, as well as basic stock-related and financial information. The first Stock Report on NORTHWEST BIO is expected to be available through the Market Scope Advisor public website at www.advisorinsight.com by mid-October following completion of the initial Report and
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
2. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
3. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Northwest Biotherapeutics Announces Change and Expansion of Management Team
6. Northwest Biotherapeutics Announces Series of Financing Arrangements
7. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Northwest Biotherapeutics Addresses Recent Market Activity
10. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
11. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 EnGeneIC, Ltd. ... the treatment of cancer through the targeted delivery ... that, together with the Asbestos Disease Research Institute ... New South Wales (NSW) Premier,s Award for Excellence ... are the hospitals that will be involved in ...
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... of carbon nanotubes is neat, but Rice University scientists are ... in new fibers created at Rice line up like a ... Angel Mart and his colleagues. , The tricky bit, according ... the journal ACS Nano , is keeping the densely ... , Left to their own devices, carbon nanotubes form clumps ...
(Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... High-quality plasmid DNA for all demanding ... Jeff Braman ,Stratagene , A new ... and reliably isolate,high-purity plasmid DNA. The convenient ... flow columns, and alcohol precipitations, while,easily accommodating ...
... versatile kit for site-directed mutagenesis of,large plasmids ... Holly Hogrefe ,Jeff Braman ,Stratagene , ... efficiencies exceeding 80%. We have created a ... The QuikChange XL,site-directed mutagenesis ...
... accurate using the Quantos cell,proliferation assay kit ... LLC , The Quantos cell proliferation ... the number of cells present in,various tissue culture ... well the kit,performed compared to another commercial fluorescence-based ...
Cached Biology Technology:A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 2A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 3A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 4High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 2High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 3High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 4Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 2Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 3Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 4
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... indicates that lowland tapir populations may continue to drop ... Researchers from the Office National de la Chasse et ... Diego Zoo Global reviewed data retrieved from camera traps ... years and compared this data to current harvest rates ... hunting tapirs in French Guiana," said Matthias Tobler, a ...
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... has made significant inroads into uncovering the genetic basis ... with overall obesity and 13 that affect fat distribution. ... a million participants, the largest genetic investigation of human ... (Genetic Investigation of ANthropometric Traits) consortium which consists ...
... may be on the way for millions of people on ... bugs. Scientists have reported a key advance in efforts to ... as a major nuisance to homeowners and a devastating pest ... a fungus that infects a common weed and found that ...
... ovarian cancer has shown single agent activity with durable disease ... international research group has reported. Dr Ursula Matulonis ... of the single-agent trial of the drug, called MLN8237, in ... for Medical Oncology (ESMO). MLN8237 selectively inhibits ...
Cached Biology News:Studies provide new insights into the genetics of obesity and fat distribution 2Studies provide new insights into the genetics of obesity and fat distribution 3Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2